When administered alone, SHP2-D26 moderately inhibited the growth of non-small cell lung cancer (NSCLC) mice xenografts, whereas its combination with osimertinib significantly reduced the growth of osimertinib-resistant xenografts [62]. Here, PTPN11 is linked to non-small cell lung carcinoma.